Frequently Asked Questions
Factors such as increase in cardiovascular diseases and rising demand for oral drugs are acting as the major drivers for the global cardioselective beta blockers market.
F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Pfizer Inc (U.S.), Lupin (India), GSK Plc (U.K.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals (U.S.), Pierre Fabre Group (France).
Asia-Pacific dominates the market due to the increase’s cases of cardiovascular diseases and the rapidly aging population.
North America has been witnessing positive growth in global cardioselective beta blockers market throughout the forecasted period due to the increase prevalence of cardiovascular complications and advanced healthcare facilities.
